Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Autologous hematopoietic stem cell transplant (ASCT) is the standard curative treatment for patients with high-risk relapsed/refractory Hodgkin lymphoma (R/R HL). The AETHERA study showed survival gain with Brentuximab Vedotin (BV) maintenance after ASCT in BV-naive patients, which was recently confirmed in the retrospective AMAHRELIS cohort, including a majority of BV-exposed patients. However, this approach has not been compared to intensive tandem auto/auto or auto/allo transplant strategies, which were used before BV approval. Here, we matched BV maintenance (AMAHRELIS) and tandem SCT (HR2009) cohorts, and observed that BV maintenance was associated with better survival outcome in patients with HR R/R HL. © 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.


A Marouf, N Molinari, D Sibon, A S Cottereau, S Kanoun, C Antoine, P E Debureaux, D Cavalieri, L M Fornecker, R O Casasnovas, C Herbaux, S Amorim, C Rossi, D Bouscary, P Brice, H Ghesquieres, J Tamburini, B Deau. Tandem versus single haematopoietic stem cell transplant and BV maintenance in relapsed/refractory Hodgkin lymphoma: A matched cohort analysis from the LYSA. British journal of haematology. 2023 Jul;202(2):379-383

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 37192755

View Full Text